{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '-', 'any AESI leading to permanent study drug discontinuation', '-', 'any AESI by maximum intensity, corrective treatment, and final outcome', '-', 'cumulative incidence at specified time points (K-M estimates at 1 week, 4 weeks,', '12 weeks, 24 weeks and 52 weeks)', 'Definitions of AESIs and the method to identify AESIs will be specified in the SAP.', '11.4.3.1.2Death', 'The following deaths summaries will be generated:', 'Number (%) of patients who died by study period (treatment emergent period, on-study)', 'and reasons for death summarized on the safety population by treatment received', 'Death in nonrandomized patients or randomized and not treated patients', 'TEAE leading to death (death as an outcome on the AE CRF page as reported by the', 'Investigator) by primary SOC, HLGT, HLT and PT showing number (%) of patients', 'sorted by internationally agreed order of SOC and alphabetic order of HLGT, HLT, and', 'PT.', 'Patient data listings will be provided for all AEs, TEAEs, SAE, AEs leading to study', 'discontinuation, AESIs and deaths.', '11.4.3.2 Clinical Laboratory Evaluation, Vital Signs and Electrocardiogram Data', 'Results and change from baseline for the parameters will be summarized by treatment group for', 'baseline and each post baseline time point, endpoint, minimum and maximum value. Summary', 'statistics will include number of patients, mean, SD, median, Q1, Q3, minimum and maximum.', 'The descriptive by visit analysis will be conducted from the baseline up to the scheduled', 'evaluation visit for all patients disregarding the treatment status of the patients at each visit as', 'long as their data is available.', 'The proportion of patients who had at least one incidence of PCSA at any time during the', 'reatment-emergent period will be summarized by treatment group. Shift tables showing changes', 'with respect to the baseline status will be provided.', 'Listings will be provided with flags indicating clinically out-of range values, as well as PCSA', 'values.', '11.4.3.3 Humoral Immune Response to Vaccines', 'For patients who receive vaccination, vaccine response parameters will be summarized by', 'treatment groups with descriptive statistics. These parameters will be defined in the SAP.', 'Property of the Sanofi Group - strictly confidential', 'Page 119', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '11.4.4 Analyses of Systemic Drug Concentration, Anti-drug Antibodies, and', 'Pharmacodynamic Variables', '11.4.4.1 Drug Concentration Analysis', 'Concentrations of functional dupilumab in serum will be summarized using arithmetic and', 'geometric means, SD, standard error of the mean (SEM), coefficient of variation (CV%),', 'minimum, median, and maximum by treatment per visit.', 'Concentrations of functional dupilumab in serum will be used for population PK analysis by non-', 'linear mixed effects modeling if warranted. Additional details of the analysis plan and the results', 'will be provided in a separate document.', '11.4.4.2 Anti-drug Antibodies Analysis', 'The incidence of positivity in the ADA assay will be assessed as absolute occurrence (n) and', 'percent of patients (%), presented by treatment groups. Listing of ADA titer levels will be', 'provided for patients positive in the ADA assay. Samples that are positive in the ADA assay will', 'be further characterized for the presence of anti-dupilumab neutralizing antibodies.', 'Plots of concentrations of functional dupilumab will be examined and the potential influence of', 'ADA on individual concentration-time profiles will be evaluated. Assessment of the potential', 'impact of ADA on safety and efficacy may be provided.', 'Anti-drug antibodies at baseline will be summarized by:', 'Number (%) of patients with a baseline sample negative in the ADA assay', 'Number (%) of patients with a baseline sample positive in the ADA assay', 'The summary statistics (including number, median, Q1, Q3, minimum, and maximum) of', 'the titer for patients positive in the ADA assay at baseline', 'Anti-drug antibody incidence and titer will be provided for the following:', 'Number (%) of patients negative in ADA assay at all times', 'Number (%) of patients positive in ADA assay at any time', 'Number (%) of patients with pre-existing positive response', 'Number (%) of patients with treatment-boosted positive response', 'Number (%) of patients with treatment-emergent positive response', 'Number (%) of patients with transient treatment-emergent positive response', 'Number (%) of patients with persistent treatment-emergent positive response', 'Number (%) of patients with indeterminate treatment-emergent positive response', 'The summary statistics (including number, median, Q1, Q3, minimum and maximum) of', 'the peak post-baseline titer for patients with treatment-emergent positive responses', 'Property of the Sanofi Group - strictly confidential', 'Page 120', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}